{
    "organizations": [],
    "uuid": "94bcb4538dbf74e305503c81ef771267095c0ab2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-roche-holding-ag-drugs-chief-says/brief-roche-holding-ag-drugs-chief-says-immunotherapy-competitors-taking-share-from-avastin-idUSFWN1PR09Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche Holding AG Drugs Chief Says Immunotherapy Competitors Taking Share From Avastin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Roche Holding Ag:\n* CFO SAYS EXPECTS HIGH THREE DIGIT MILLION TAX BENEFIT FROM U.S. TAX REFORM\n* CEO SAYS U.S. TAX REFORM HAS BOOSTED U.S. COMPETITIVENESS\n* DRUGS DIVISION CHIEF SAYS OCREVUS HAS 5 PERCENT MULTIPLE SCLEROSIS MARKET SHARE AFTER THREE QUARTERS OF SALES, SEES NO SLOWING IN UNITED STATES\n* CEO EXPECTS OCREVUS TO “EASILY” EXCEED 1 BILLION SFR IN SALES IN 2018\n* DRUGS CHIEF EXPECTS SIMILAR EROSION FOR HERCEPTIN AS RITUXAN AS BIOSIMILARS ENTER MARKET\n* DRUGS CHIEF SAYS IMMUNOTHERAPY COMPETITORS TAKING MARKET SHARE FROM AVASTIN IN U.S. LUNG CANCER TREATMENT, RESULTING IN REVENUE DECLINE Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ",
    "published": "2018-02-01T17:07:00.000+02:00",
    "crawled": "2018-02-02T12:50:02.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "cfo",
        "say",
        "expects",
        "high",
        "three",
        "digit",
        "million",
        "tax",
        "benefit",
        "tax",
        "reform",
        "ceo",
        "say",
        "tax",
        "reform",
        "boosted",
        "competitiveness",
        "drug",
        "division",
        "chief",
        "say",
        "ocrevus",
        "percent",
        "multiple",
        "sclerosis",
        "market",
        "share",
        "three",
        "quarter",
        "sale",
        "see",
        "slowing",
        "united",
        "state",
        "ceo",
        "expects",
        "ocrevus",
        "easily",
        "exceed",
        "billion",
        "sfr",
        "sale",
        "drug",
        "chief",
        "expects",
        "similar",
        "erosion",
        "herceptin",
        "rituxan",
        "biosimilars",
        "enter",
        "market",
        "drug",
        "chief",
        "say",
        "immunotherapy",
        "competitor",
        "taking",
        "market",
        "share",
        "avastin",
        "lung",
        "cancer",
        "treatment",
        "resulting",
        "revenue",
        "decline",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "john",
        "miller"
    ]
}